Related Experiment Video
Updated: Jun 19, 2026
04:56
In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
Fluticasone propionate in COPD airway inflammation: there is a partial effect
Sabina A Antoniu1, Claudio F Donner
1Division of Pulmonary Diseases, Salvatore Maugeri Foundation IRCCS, via per Revislate 13, Veruno 28010 (NO), Italy. santoniu@fsm.it
Expert Review of Pharmacoeconomics & Outcomes Research
|October 8, 2009
Summary
Inhaled fluticasone propionate offers partial relief for chronic obstructive pulmonary disease (COPD) symptoms and reduces exacerbations but does not halt lung function decline. This study investigated its impact on COPD inflammation and progression.
Area of Science:
- Pulmonary Medicine
- Inflammatory Diseases
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a major global health issue, primarily linked to smoking and characterized by chronic airway inflammation and obstruction.
- T-lymphocytes play an emerging role in COPD pathogenesis, particularly in smokers.
- Current treatments offer limited efficacy, with oral steroids benefiting only about 10% of patients.
Discussion:
- Inhaled fluticasone propionate demonstrated a partial impact on bronchial inflammation in COPD patients.
- The study analyzed the effects of fluticasone propionate on inflammatory cells within bronchial biopsies.
- While fluticasone propionate did not halt progressive airway obstruction, it showed potential in symptom management.
Key Insights:
- Fluticasone propionate partially reduced airway inflammation and the number of COPD exacerbations.
- The treatment did not influence the progression of chronic airway obstruction in COPD.
- A partial improvement in patient-reported symptoms was observed with fluticasone propionate use.
Outlook:
- Further research is needed to explore combination therapies for more effective COPD management.
- Investigating novel therapeutic targets beyond current anti-inflammatory approaches is crucial.
- Understanding the specific roles of different inflammatory cells may lead to personalized COPD treatments.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...